{
    "hands_on_practices": [
        {
            "introduction": "At the heart of Mendelian randomization lies the Wald ratio, an elegant method for estimating a causal effect from two separate associations. This practice will guide you through the fundamental calculation of a two-sample MR analysis. By taking the ratio of a gene-outcome association to a gene-exposure association, you will compute a causal estimate and learn to quantify its statistical uncertainty, a core skill for interpreting MR results .",
            "id": "4611689",
            "problem": "A single genetic variant is proposed as an instrumental variable for a continuous exposure in a two-sample Mendelian randomization (MR) analysis. Assume the standard instrumental variable conditions hold: relevance (the genetic variant affects the exposure), independence (the genetic variant is independent of confounders of the exposure-outcome relationship), and exclusion restriction (the genetic variant affects the outcome only through the exposure). In a large sample from Study A, a linear regression of the exposure on the genetic variant yields a summary association estimate $\\hat{\\beta}_{XG}$ with standard error $SE(\\hat{\\beta}_{XG})$. In an independent large sample from Study B, a logistic regression of the binary outcome on the same genetic variant yields a log-odds association estimate $\\hat{\\beta}_{YG}$ with standard error $SE(\\hat{\\beta}_{YG})$. Treat the two samples as independent and interpret the effect of the genetic variant on the outcome on the log-odds scale.\n\nYou are given the following summary statistics:\n- Study A: $\\hat{\\beta}_{XG} = 0.08$ and $SE(\\hat{\\beta}_{XG}) = 0.01$.\n- Study B: $\\hat{\\beta}_{YG} = 0.024$ and $SE(\\hat{\\beta}_{YG}) = 0.006$.\n\nUsing the core instrumental variable identity that under these assumptions the causal effect equals the ratio of the genetic association with the outcome to the genetic association with the exposure, construct the ratio estimator for the causal log-odds effect of the exposure on the outcome. Then, using a first-order Taylor series (delta method) approximation for a smooth function of independent estimates, derive the approximate standard error of the ratio estimator. Finally, compute the Wald test statistic $z = \\hat{\\beta}_{W} / SE(\\hat{\\beta}_{W})$ for testing the null hypothesis that the causal effect is zero.\n\nReport only the value of $z$, rounded to four significant figures. Do not include any units in your final answer.",
            "solution": "The user wants to compute the Wald test statistic for a causal effect estimated using two-sample Mendelian randomization (MR).\n\n### Step 1: Problem Validation\nThe problem statement is validated according to the specified criteria.\n\n**1. Extract Givens:**\n- A single genetic variant is an instrumental variable (IV) for a continuous exposure ($X$) and a binary outcome ($Y$).\n- The three core IV assumptions (relevance, independence, exclusion restriction) are assumed to hold.\n- The analysis is a two-sample MR, with estimates from two independent studies.\n- Study A (exposure sample):\n    - Genetic association with exposure: $\\hat{\\beta}_{XG} = 0.08$.\n    - Standard error of the association: $SE(\\hat{\\beta}_{XG}) = 0.01$.\n- Study B (outcome sample):\n    - Genetic association with the log-odds of the outcome: $\\hat{\\beta}_{YG} = 0.024$.\n    - Standard error of the association: $SE(\\hat{\\beta}_{YG}) = 0.006$.\n- The task is to compute the Wald test statistic $z = \\hat{\\beta}_{W} / SE(\\hat{\\beta}_{W})$ for the null hypothesis of no causal effect, where $\\hat{\\beta}_{W}$ is the ratio estimator of the causal effect.\n\n**2. Validate Using Extracted Givens:**\n- **Scientifically Grounded:** The problem describes a standard two-sample Mendelian randomization analysis, a widely used and validated method in epidemiology. The instrumental variable assumptions, the ratio estimator, and the use of the delta method are all core components of this methodology.\n- **Well-Posed:** The problem provides all necessary data and clearly specifies the methods to be used (ratio estimation, delta method) to compute a single, well-defined quantity (the Wald statistic).\n- **Objective:** The problem is stated using precise, quantitative, and objective language.\n\n**3. Verdict and Action:**\nThe problem is scientifically sound, well-posed, objective, and complete. It is therefore deemed **valid**. The solution will now be constructed.\n\n### Step 2: Solution\nThe causal effect of the exposure $X$ on the log-odds of the outcome $Y$ is denoted by $\\beta_W$. Under the instrumental variable assumptions, the genetic association with the outcome ($\\beta_{YG}$) is the product of the causal effect and the genetic association with the exposure ($\\beta_{XG}$):\n$$ \\beta_{YG} = \\beta_W \\cdot \\beta_{XG} $$\nThe ratio estimator, also known as the Wald estimator, for the causal effect is therefore given by the ratio of the two association estimates:\n$$ \\hat{\\beta}_W = \\frac{\\hat{\\beta}_{YG}}{\\hat{\\beta}_{XG}} $$\nUsing the provided values, we can compute the point estimate of the causal effect:\n$$ \\hat{\\beta}_W = \\frac{0.024}{0.08} = 0.3 $$\nThis value represents an estimated increase of $0.3$ in the log-odds of the outcome for each one-unit increase in the exposure.\n\nTo construct the Wald test statistic, we need the standard error of this estimator, $SE(\\hat{\\beta}_W)$. The problem specifies using a first-order Taylor series approximation (the delta method) to find this. Let our estimator be a function of two random variables, $f(x, y) = y/x$, where $x = \\hat{\\beta}_{XG}$ and $y = \\hat{\\beta}_{YG}$. The variance of this function can be approximated as:\n$$ \\text{Var}(f(x, y)) \\approx \\left(\\frac{\\partial f}{\\partial x}\\right)^2 \\text{Var}(x) + \\left(\\frac{\\partial f}{\\partial y}\\right)^2 \\text{Var}(y) + 2 \\left(\\frac{\\partial f}{\\partial x}\\right) \\left(\\frac{\\partial f}{\\partial y}\\right) \\text{Cov}(x, y) $$\nThe partial derivatives of $f(x, y)$ are:\n$$ \\frac{\\partial f}{\\partial x} = -\\frac{y}{x^2} \\quad \\text{and} \\quad \\frac{\\partial f}{\\partial y} = \\frac{1}{x} $$\nSince the estimates $\\hat{\\beta}_{XG}$ and $\\hat{\\beta}_{YG}$ come from two independent samples, their covariance is zero, i.e., $\\text{Cov}(\\hat{\\beta}_{XG}, \\hat{\\beta}_{YG}) = 0$. The variance formula simplifies to:\n$$ \\text{Var}(\\hat{\\beta}_W) \\approx \\left(-\\frac{\\hat{\\beta}_{YG}}{\\hat{\\beta}_{XG}^2}\\right)^2 \\text{Var}(\\hat{\\beta}_{XG}) + \\left(\\frac{1}{\\hat{\\beta}_{XG}}\\right)^2 \\text{Var}(\\hat{\\beta}_{YG}) $$\nThe variance of an estimate is the square of its standard error, so $\\text{Var}(\\hat{\\beta}) = [SE(\\hat{\\beta})]^2$. Substituting this relationship into the formula gives the expression for the squared standard error of the causal effect estimate:\n$$ [SE(\\hat{\\beta}_W)]^2 \\approx \\frac{\\hat{\\beta}_{YG}^2}{\\hat{\\beta}_{XG}^4} [SE(\\hat{\\beta}_{XG})]^2 + \\frac{1}{\\hat{\\beta}_{XG}^2} [SE(\\hat{\\beta}_{YG})]^2 $$\nNow we substitute the given numerical values:\n- $\\hat{\\beta}_{XG} = 0.08$\n- $SE(\\hat{\\beta}_{XG}) = 0.01$\n- $\\hat{\\beta}_{YG} = 0.024$\n- $SE(\\hat{\\beta}_{YG}) = 0.006$\n\n$$ [SE(\\hat{\\beta}_W)]^2 \\approx \\frac{(0.024)^2}{(0.08)^4} (0.01)^2 + \\frac{1}{(0.08)^2} (0.006)^2 $$\n$$ [SE(\\hat{\\beta}_W)]^2 \\approx \\frac{0.000576}{0.00004096} (0.0001) + \\frac{1}{0.0064} (0.000036) $$\n$$ [SE(\\hat{\\beta}_W)]^2 \\approx (14.0625) \\times (0.0001) + (156.25) \\times (0.000036) $$\n$$ [SE(\\hat{\\beta}_W)]^2 \\approx 0.00140625 + 0.005625 $$\n$$ [SE(\\hat{\\beta}_W)]^2 \\approx 0.00703125 $$\nThe standard error is the square root of the variance:\n$$ SE(\\hat{\\beta}_W) = \\sqrt{0.00703125} \\approx 0.08385256... $$\nFinally, we compute the Wald test statistic, $z$, for the null hypothesis $H_0: \\beta_W = 0$:\n$$ z = \\frac{\\hat{\\beta}_W}{SE(\\hat{\\beta}_W)} $$\n$$ z = \\frac{0.3}{0.08385256...} \\approx 3.57770876... $$\nRounding to four significant figures, we get:\n$$ z \\approx 3.578 $$",
            "answer": "$$\\boxed{3.578}$$"
        },
        {
            "introduction": "A Mendelian randomization study is only as reliable as the genetic instruments it employs. The \"Relevance\" assumption requires that these instruments are strongly associated with the exposure, as weak instruments can lead to biased results. This exercise will teach you how to quantify instrument strength by calculating the first-stage $R^2$, the proportion of variance in the exposure explained by the genetic variants, using only summary-level data .",
            "id": "4611703",
            "problem": "A researcher is conducting a Mendelian randomization analysis using multiple independent single nucleotide polymorphisms (SNPs) as instruments for a continuous exposure. The first-stage model is a linear regression of the exposure on each SNP coded additively as allele counts in $\\{0,1,2\\}$. Assume the following widely accepted facts hold:\n- Under Hardy–Weinberg equilibrium (HWE), if the effect allele frequency is $p$, then the additive genotype has variance $\\operatorname{Var}(G)=2p(1-p)$.\n- In a simple linear regression of a continuous exposure $X$ on a single regressor $G$, the proportion of variance in $X$ explained by $G$ is $R^{2}=\\operatorname{Var}\\left(\\mathbb{E}[X\\mid G]\\right)/\\operatorname{Var}(X)$.\n- When including multiple independent regressors $\\{G_{i}\\}$, the variance explained by their linear combination is the sum of the explained variances because covariances are zero.\n\nYou are given summary association estimates from a Genome-Wide Association Study (GWAS) of the exposure for $4$ independent SNPs. For SNP $i$, denote by $\\hat{\\beta}_{XG,i}$ the estimated per-allele association with the exposure and by $p_{i}$ the effect allele frequency. The exposure variance in the GWAS sample is $\\operatorname{Var}(X)=0.81$.\n\nData:\n- SNP A: $p_{A}=0.30$, $\\hat{\\beta}_{XG,A}=0.08$.\n- SNP B: $p_{B}=0.45$, $\\hat{\\beta}_{XG,B}=0.05$.\n- SNP C: $p_{C}=0.15$, $\\hat{\\beta}_{XG,C}=0.10$.\n- SNP D: $p_{D}=0.10$, $\\hat{\\beta}_{XG,D}=0.04$.\n\nTasks:\n1. Starting from the definitions above and without invoking any pre-stated target formula, derive a closed-form expression for the first-stage variance explained $R^{2}_{i}$ by a single SNP $i$ in terms of $p_{i}$, $\\hat{\\beta}_{XG,i}$, and $\\operatorname{Var}(X)$.\n2. Using the independence of the SNPs, generalize your expression to obtain the combined first-stage variance explained $R^{2}_{\\text{total}}$ by the instrument set $\\{\\text{A},\\text{B},\\text{C},\\text{D}\\}$.\n3. Compute $R^{2}_{\\text{total}}$ as a decimal. Round your final answer to $4$ significant figures. Express your answer as a pure number (unitless).",
            "solution": "The user has provided a problem in the field of genetic epidemiology, specifically concerning Mendelian randomization (MR). The task is to derive an expression for the variance in an exposure explained by genetic instruments and then to compute this value using provided summary statistics.\n\n### Problem Validation\n\nFirst, the problem statement must be validated for scientific soundness, clarity, and completeness.\n\n**Step 1: Extract Givens**\n-   The first-stage model is a linear regression of a continuous exposure $X$ on a single nucleotide polymorphism (SNP) $G_i$, where $G_i$ is coded additively as the number of effect alleles, taking values in $\\{0, 1, 2\\}$.\n-   Under Hardy-Weinberg equilibrium (HWE), the variance of an additive genotype $G$ is given by $\\operatorname{Var}(G)=2p(1-p)$, where $p$ is the effect allele frequency.\n-   The proportion of variance in $X$ explained by $G$, denoted $R^2$, is defined as $R^{2}=\\operatorname{Var}\\left(\\mathbb{E}[X\\mid G]\\right)/\\operatorname{Var}(X)$.\n-   For multiple independent SNPs $\\{G_i\\}$, the total variance explained is the sum of the variances explained by each SNP individually.\n-   The analysis involves $4$ independent SNPs: A, B, C, and D.\n-   For each SNP $i$, the per-allele association estimate is $\\hat{\\beta}_{XG,i}$ and the effect allele frequency is $p_i$.\n-   The variance of the exposure is $\\operatorname{Var}(X)=0.81$.\n-   Data provided:\n    -   SNP A: $p_{A}=0.30$, $\\hat{\\beta}_{XG,A}=0.08$.\n    -   SNP B: $p_{B}=0.45$, $\\hat{\\beta}_{XG,B}=0.05$.\n    -   SNP C: $p_{C}=0.15$, $\\hat{\\beta}_{XG,C}=0.10$.\n    -   SNP D: $p_{D}=0.10$, $\\hat{\\beta}_{XG,D}=0.04$.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientifically Grounded:** The problem is firmly rooted in the established statistical and genetic principles underlying Mendelian randomization. The formula $\\operatorname{Var}(G)=2p(1-p)$ is a standard result for an additively coded SNP under HWE. The definition of $R^2$ is a fundamental concept in regression analysis. The method of combining explained variance from independent predictors is also standard. All concepts are central to the field of genetic epidemiology.\n-   **Well-Posed:** The problem is clearly structured into three tasks: derivation, generalization, and computation. The provided data are sufficient and necessary to complete all tasks. The question leads to a unique and meaningful solution.\n-   **Objective:** The problem is stated in precise, technical language, free from any subjectivity or ambiguity.\n\n**Step 3: Verdict and Action**\nThe problem is scientifically sound, well-posed, and objective. It meets all criteria for a valid problem. Therefore, a full solution will be provided.\n\n---\n\n### Solution Derivation and Calculation\n\n**Task 1: Derive a closed-form expression for $R^{2}_{i}$ for a single SNP.**\n\nThe first-stage model is a simple linear regression of the exposure $X$ on the genotype $G_i$ for a single SNP $i$. The conditional expectation of $X$ given $G_i$ is:\n$$\n\\mathbb{E}[X \\mid G_i] = \\alpha_i + \\beta_{XG,i} G_i\n$$\nwhere $\\beta_{XG,i}$ is the per-allele association of the SNP with the exposure.\n\nThe proportion of variance in $X$ explained by $G_i$, denoted $R^2_i$, is given by the definition:\n$$\nR^2_i = \\frac{\\operatorname{Var}(\\mathbb{E}[X \\mid G_i])}{\\operatorname{Var}(X)}\n$$\n\nWe need to find the variance of the conditional expectation, which is the numerator. Using the properties of variance, where $\\alpha_i$ and $\\beta_{XG,i}$ are considered fixed coefficients from the regression:\n$$\n\\operatorname{Var}(\\mathbb{E}[X \\mid G_i]) = \\operatorname{Var}(\\alpha_i + \\beta_{XG,i} G_i) = \\beta_{XG,i}^2 \\operatorname{Var}(G_i)\n$$\n\nThe problem states that under HWE, the variance of the additively coded genotype $G_i$ is:\n$$\n\\operatorname{Var}(G_i) = 2p_i(1-p_i)\n$$\nwhere $p_i$ is the effect allele frequency of SNP $i$.\n\nSubstituting this expression for $\\operatorname{Var}(G_i)$ into the equation for the variance of the conditional expectation, we get:\n$$\n\\operatorname{Var}(\\mathbb{E}[X \\mid G_i]) = \\beta_{XG,i}^2 [2p_i(1-p_i)]\n$$\n\nFinally, substituting this result back into the definition of $R^2_i$, we obtain the closed-form expression. In practice, we use the estimated coefficient $\\hat{\\beta}_{XG,i}$ from a GWAS, so the estimated variance explained is:\n$$\nR^2_i = \\frac{2p_i(1-p_i)\\hat{\\beta}_{XG,i}^2}{\\operatorname{Var}(X)}\n$$\nThis completes the first task.\n\n**Task 2: Generalize the expression for the combined first-stage variance explained $R^{2}_{\\text{total}}$.**\n\nThe problem states that the $4$ SNPs are independent. A key property of independent random variables is that the variance explained by a linear model containing them is the sum of the variances explained by each variable individually. Therefore, the total proportion of variance explained, $R^2_{\\text{total}}$, is the sum of the individual $R^2_i$ values for each SNP in the set $\\{\\text{A}, \\text{B}, \\text{C}, \\text{D}\\}$.\n$$\nR^2_{\\text{total}} = \\sum_{i \\in \\{\\text{A,B,C,D}\\}} R^2_i\n$$\n\nSubstituting the expression derived in Task 1:\n$$\nR^2_{\\text{total}} = \\sum_{i \\in \\{\\text{A,B,C,D}\\}} \\frac{2p_i(1-p_i)\\hat{\\beta}_{XG,i}^2}{\\operatorname{Var}(X)}\n$$\n\nSince $\\operatorname{Var}(X)$ and the factor of $2$ are common to all terms, we can write the expression as:\n$$\nR^2_{\\text{total}} = \\frac{2}{\\operatorname{Var}(X)} \\sum_{i \\in \\{\\text{A,B,C,D}\\}} p_i(1-p_i)\\hat{\\beta}_{XG,i}^2\n$$\nThis is the generalized expression for the combined variance explained.\n\n**Task 3: Compute $R^{2}_{\\text{total}}$ as a decimal rounded to 4 significant figures.**\n\nWe are given $\\operatorname{Var}(X) = 0.81$. We will now compute the term $p_i(1-p_i)\\hat{\\beta}_{XG,i}^2$ for each of the four SNPs.\n\n-   **SNP A:**\n    $p_A(1-p_A)\\hat{\\beta}_{XG,A}^2 = (0.30)(1-0.30)(0.08)^2 = (0.30)(0.70)(0.0064) = (0.21)(0.0064) = 0.001344$\n\n-   **SNP B:**\n    $p_B(1-p_B)\\hat{\\beta}_{XG,B}^2 = (0.45)(1-0.45)(0.05)^2 = (0.45)(0.55)(0.0025) = (0.2475)(0.0025) = 0.00061875$\n\n-   **SNP C:**\n    $p_C(1-p_C)\\hat{\\beta}_{XG,C}^2 = (0.15)(1-0.15)(0.10)^2 = (0.15)(0.85)(0.01) = (0.1275)(0.01) = 0.001275$\n\n-   **SNP D:**\n    $p_D(1-p_D)\\hat{\\beta}_{XG,D}^2 = (0.10)(1-0.10)(0.04)^2 = (0.10)(0.90)(0.0016) = (0.09)(0.0016) = 0.000144$\n\nNext, we sum these values:\n$$\n\\sum_{i} p_i(1-p_i)\\hat{\\beta}_{XG,i}^2 = 0.001344 + 0.00061875 + 0.001275 + 0.000144 = 0.00338175\n$$\n\nNow, we use the formula for $R^2_{\\text{total}}$:\n$$\nR^2_{\\text{total}} = \\frac{2}{\\operatorname{Var}(X)} \\sum_{i} p_i(1-p_i)\\hat{\\beta}_{XG,i}^2 = \\frac{2}{0.81} (0.00338175)\n$$\n$$\nR^2_{\\text{total}} = \\frac{0.0067635}{0.81} = 0.00835\n$$\nThe result is exactly $0.00835$. The problem requires rounding the final answer to $4$ significant figures. The non-zero significant figures are $8$, $3$, and $5$. To express this with four significant figures, we add a zero at the end.\n\n$R^2_{\\text{total}} \\approx 0.008350$.",
            "answer": "$$\n\\boxed{0.008350}\n$$"
        },
        {
            "introduction": "The most challenging assumption in Mendelian randomization is the \"Exclusion Restriction,\" which states that a genetic instrument affects the outcome only through the exposure. While this is untestable for your primary outcome, a negative control study offers a powerful way to detect violations. This practice challenges you to design a methodologically sound negative control experiment, a crucial technique for building confidence in the validity of your instruments and the credibility of your causal claims .",
            "id": "2404125",
            "problem": "You are planning a negative control Mendelian randomization (MR) study to evaluate the validity of genetic instruments for low-density lipoprotein cholesterol (LDL-C) when studying vascular outcomes. Let $G$ denote a set of Single Nucleotide Polymorphisms (SNPs) that are robustly associated with LDL-C (the exposure, $X$). Let $Y$ denote a vascular outcome such as coronary artery disease, and let $Y^{\\ast}$ denote a proposed negative control outcome, accidental death, which is not biologically plausibly caused by LDL-C. You have access to summary-level Genome-Wide Association Study (GWAS) results for $X$ and for $Y^{\\ast}$ from large cohorts of predominantly European ancestry, and you can restrict analyses to unrelated individuals. The primary goal is to design and analyze a negative control MR to assess whether the instruments plausibly satisfy the exclusion restriction for $Y$, by testing whether $G$ shows no causal effect on $Y^{\\ast}$.\n\nWhich analysis plan most appropriately implements this negative control MR in a way that is consistent with first principles and yields interpretable evidence on instrument validity?\n\nA. Use a single-sample design by computing a weighted polygenic score from $G$ in the cohort with accidental death, and fit a logistic regression of $Y^{\\ast}$ on the polygenic score while adjusting for LDL-C, age, sex, and principal components. Declare success if the $p$-value exceeds $0.05$ and interpret the null association as proof of validity.\n\nB. Use a $2$-sample MR design with non-overlapping samples: select independent LDL-C SNPs $G$ (pruned for Linkage Disequilibrium (LD)), harmonize alleles, and estimate the $G$–$Y^{\\ast}$ causal effect using the Inverse-Variance Weighted (IVW) estimator as primary, complemented by Mendelian randomization-Egger (MR-Egger), weighted median, and leave-one-out analyses. Restrict to a single ancestry and adjust $G$–phenotype associations for population structure (e.g., Principal Components (PCs)). Evaluate horizontal pleiotropy with the MR-Egger intercept and heterogeneity with Cochran’s $Q$. Use the Steiger directionality test to ensure $G$ explains more variance in $X$ than in $Y^{\\ast}$. Conclude that the instruments pass the negative control if the $G$–$Y^{\\ast}$ causal estimate is null across sensitivity analyses and there is no evidence of unbalanced pleiotropy, thereby supporting the exclusion restriction for vascular outcomes.\n\nC. Fit a regression of $Y^{\\ast}$ on a polygenic score for LDL-C while adjusting for smoking and education to remove measured confounding, allow sample overlap between the LDL-C and accidental death cohorts to maximize power, and interpret a non-significant association as evidence that the instruments are valid.\n\nD. Maximize power by including all SNPs associated with LDL-C regardless of strength or LD, create a genome-wide polygenic score, and test for association with $Y^{\\ast}$. If any association is detected, attribute it to selection or collider bias in $Y^{\\ast}$ and proceed to use the instruments for $Y$ without further sensitivity analyses.\n\nE. Skip the negative control and instead verify that $G$ is associated with a positive control outcome (e.g., $Y$) in a $2$-sample MR using IVW only; if the effect is significant, infer that $G$ is valid for all downstream applications, including vascular outcomes.",
            "solution": "The problem statement asks for the most appropriate analysis plan for a negative control Mendelian randomization (MR) study. The objective is to use a negative control outcome, $Y^{\\ast}$ (accidental death), to evaluate the validity of genetic instruments, $G$, for an exposure, $X$ (LDL-C), in the context of studying a primary outcome, $Y$ (vascular disease). Specifically, we are to assess the plausibility of the exclusion restriction assumption.\n\nBefore proceeding, the problem statement must be validated.\n\n**Step 1: Extract Givens**\n-   Genetic instruments ($G$): A set of Single Nucleotide Polymorphisms (SNPs) robustly associated with LDL-C.\n-   Exposure ($X$): Low-density lipoprotein cholesterol (LDL-C).\n-   Primary outcome ($Y$): Vascular outcome (e.g., coronary artery disease).\n-   Negative control outcome ($Y^{\\ast}$): Accidental death, assumed not to be causally influenced by $X$.\n-   Available Data: Summary-level Genome-Wide Association Study (GWAS) results for $X$ and $Y^{\\ast}$ from large cohorts of predominantly European ancestry. Analyses can be restricted to unrelated individuals.\n-   Objective: Design a negative control MR to test if $G$ has a causal effect on $Y^{\\ast}$ to assess the plausibility of the exclusion restriction assumption for the $G \\rightarrow X \\rightarrow Y$ analysis.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded. Mendelian randomization is a valid method for causal inference. The use of a negative control outcome is a standard and important technique for detecting violations of MR assumptions, particularly the exclusion restriction, which is untestable otherwise. The choice of LDL-C, vascular outcomes, and accidental death is Biologically plausible. The problem is well-posed, providing sufficient information (summary-level GWAS data, defined exposure/outcomes) to design a standard two-sample MR study. There are no internal contradictions, unrealistic requirements, or ambiguities. The language is precise and objective.\n\n**Step 3: Verdict and Action**\nThe problem is valid. We will proceed to derive the correct methodology and evaluate the given options.\n\n**Derivation of Correct Methodology from First Principles**\n\nThe validity of a genetic instrument $G$ for estimating the causal effect of an exposure $X$ on an outcome $Y$ rests on three core assumptions:\n1.  **Relevance (IV1):** The instrument $G$ must be associated with the exposure $X$. Formally, $G \\not\\perp X$.\n2.  **Exclusion Restriction (IV2):** The instrument $G$ must not affect the outcome $Y$ through any pathway other than through the exposure $X$. Formally, $G \\perp Y | X, U$, where $U$ represents all confounders. A common violation of this is horizontal pleiotropy, where $G$ has a direct effect on $Y$.\n3.  **Independence (IV3):** The instrument $G$ must be independent of any unmeasured confounders $U$ that bias the conventional observational association between $X$ and $Y$. Formally, $G \\perp U$.\n\nThe exclusion restriction (IV2) is the most difficult assumption to verify. A negative control experiment provides a partial test. We select a negative control outcome, $Y^{\\ast}$, for which the causal effect of $X$ is known to be zero. If we conduct an MR analysis of $X$ on $Y^{\\ast}$, the estimated causal effect should be null, provided the instrument $G$ is valid.\n\nThe causal estimate in a two-sample MR setting is derived from the ratio of the SNP-outcome association ($\\hat{\\beta}_{GY^{\\ast}}$) to the SNP-exposure association ($\\hat{\\beta}_{GX}}$). If we observe a statistically significant non-zero effect of $G$ on $Y^{\\ast}$, this cannot be mediated by $X$ (since the true $X \\rightarrow Y^{\\ast}$ effect is zero). Therefore, the non-zero effect must arise from a violation of the MR assumptions for the $G \\rightarrow Y^{\\ast}$ analysis, most likely a pleiotropic pathway ($G \\rightarrow Y^{\\ast}$) that bypasses $X$. Since horizontal pleiotropy is a characteristic of the genetic variant itself, its presence in the $G \\rightarrow Y^{\\ast}$ analysis strongly implies it will also be present in the primary $G \\rightarrow Y$ analysis, thereby invalidating the instruments.\n\nA robust analysis plan using the provided summary-level GWAS data must include:\n-   A **two-sample MR design**, using non-overlapping samples for the $G-X$ and $G-Y^{\\ast}$ associations to prevent bias.\n-   Careful **instrument selection**: SNPs must be strongly associated with the exposure ($p < 5 \\times 10^{-8}$) and pruned for linkage disequilibrium (LD) to ensure they are independent.\n-   **Data harmonization**: Alleles and their effect sizes must be correctly aligned between the two GWAS summary datasets.\n-   A **primary analysis method**, typically Inverse-Variance Weighted (IVW) MR, which provides the highest statistical power under the assumption of no pleiotropy or balanced pleiotropy.\n-   A comprehensive suite of **sensitivity analyses** to detect and account for pleiotropy. This includes:\n    -   **MR-Egger regression**: Its intercept provides a formal test for directional (unbalanced) pleiotropy.\n    -   **Weighted median estimator**: Provides a robust estimate if up to $50\\%$ of the instruments are invalid.\n    -   **Tests for heterogeneity**: Cochran's $Q$ statistic tests for variability in the causal estimates from individual SNPs, which is an indicator of pleiotropy.\n    -   **Leave-one-out analysis**: Identifies influential SNPs.\n-   **Additional quality control**, such as the **Steiger directionality test** to confirm that the instruments explain more variance in the exposure $X$ than in the outcome $Y^{\\ast}$, which is expected if the causal direction is $G \\rightarrow X \\rightarrow Y^{\\ast}$.\n-   **Control for population stratification**, by restricting the analysis to a single ancestry and using summary statistics that have been adjusted for population structure (e.g., via principal components).\n-   **Cautious interpretation**: A null finding for the $G-Y^{\\ast}$ association across all analyses *supports*, but does not definitively *prove*, instrument validity. A significant finding casts serious doubt on the instruments.\n\n**Evaluation of Options**\n\n**A. Use a single-sample design by computing a weighted polygenic score from $G$ in the cohort with accidental death, and fit a logistic regression of $Y^{\\ast}$ on the polygenic score while adjusting for LDL-C, age, sex, and principal components. Declare success if the $p$-value exceeds $0.05$ and interpret the null association as proof of validity.**\nThis approach is fundamentally flawed. Adjusting for the exposure (LDL-C) in a regression of the outcome on the instrument is a grave error. This conditioning blocks the very causal pathway MR is designed to utilize ($G \\rightarrow X \\rightarrow Y^{\\ast}$) and introduces collider bias. Furthermore, interpreting a $p$-value greater than $0.05$ as \"proof\" of validity is a naive and incorrect application of statistical hypothesis testing.\n**Verdict: Incorrect.**\n\n**B. Use a $2$-sample MR design with non-overlapping samples: select independent LDL-C SNPs $G$ (pruned for Linkage Disequilibrium (LD)), harmonize alleles, and estimate the $G$–$Y^{\\ast}$ causal effect using the Inverse-Variance Weighted (IVW) estimator as primary, complemented by Mendelian randomization-Egger (MR-Egger), weighted median, and leave-one-out analyses. Restrict to a single ancestry and adjust $G$–phenotype associations for population structure (e.g., Principal Components (PCs)). Evaluate horizontal pleiotropy with the MR-Egger intercept and heterogeneity with Cochran’s $Q$. Use the Steiger directionality test to ensure $G$ explains more variance in $X$ than in $Y^{\\ast}$. Conclude that the instruments pass the negative control if the $G$–$Y^{\\ast}$ causal estimate is null across sensitivity analyses and there is no evidence of unbalanced pleiotropy, thereby supporting the exclusion restriction for vascular outcomes.**\nThis option meticulously describes the current best practice for a two-sample summary-data MR analysis. It correctly specifies the use of non-overlapping samples, proper instrument selection, data harmonization, a primary IVW analysis, and a complete set of sensitivity analyses (MR-Egger, weighted median, heterogeneity, leave-one-out) to rigorously test for pleiotropy. It also includes crucial quality control steps like the Steiger test and control for population structure. The final interpretation is appropriately cautious, stating that a null result \"supports\" the assumption rather than proving it.\n**Verdict: Correct.**\n\n**C. Fit a regression of $Y^{\\ast}$ on a polygenic score for LDL-C while adjusting for smoking and education to remove measured confounding, allow sample overlap between the LDL-C and accidental death cohorts to maximize power, and interpret a non-significant association as evidence that the instruments are valid.**\nThis option contains multiple errors. First, allowing significant sample overlap in a two-sample MR design induces bias toward the confounded observational estimate, especially with weak instruments; this negates the purpose of the design. While methods to correct for overlap exist, recommending overlap to \"maximize power\" is poor advice. Second, it neglects the critical suite of sensitivity analyses required to detect pleiotropy. Third, the interpretation is again overly simplistic.\n**Verdict: Incorrect.**\n\n**D. Maximize power by including all SNPs associated with LDL-C regardless of strength or LD, create a genome-wide polygenic score, and test for association with $Y^{\\ast}$. If any association is detected, attribute it to selection or collider bias in $Y^{\\ast}$ and proceed to use the instruments for $Y$ without further sensitivity analyses.**\nThis proposal is scientifically indefensible. Including weak instruments biases MR estimates. Including SNPs in LD violates the independence assumption of standard MR estimators, leading to incorrect standard errors. Most egregiously, the plan is to perform a test and then, if the test reveals a problem (a non-null association), to ignore the result by attributing it to some other bias without evidence and proceeding with flawed instruments. This represents a willful disregard for scientific methodology.\n**Verdict: Incorrect.**\n\n**E. Skip the negative control and instead verify that $G$ is associated with a positive control outcome (e.g., $Y$) in a $2$-sample MR using IVW only; if the effect is significant, infer that $G$ is valid for all downstream applications, including vascular outcomes.**\nThis option misses the entire point of the problem. It proposes a positive control experiment, not a negative control. A positive control can confirm that the study has sufficient power, but it cannot test the exclusion restriction assumption. A pleiotropic instrument can easily produce a significant effect on a positive control outcome. Relying on IVW only is inadequate, and inferring universal validity from a single positive result is a dangerous oversimplification.\n**Verdict: Incorrect.**\n\nIn summary, only Option B presents a methodologically sound, comprehensive, and correctly interpreted plan for a negative control MR study.",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}